Joshua Dinapoli | Global Project Head mRNA Platform Development
Sanofi Pasteur

Joshua Dinapoli, Global Project Head mRNA Platform Development, Sanofi Pasteur

Joshua DiNapoli received his PhD in Microbiology and Immunology from the University of Rochester in 2005, where he performed work in the lab of Dr. Robert C. Rose on virus-like particle vaccines against human papillomavirus. He went on to perform his post-doctoral work in the lab of Dr. Peter L. Collins at the National Institute of Allergy and Infectious Diseases from 2005 to 2010 where he developed live-attenuated vaccine candidates against RSV, highly pathogenic avian influenza, severe acute respiratory syndrome-associated coronavirus, and Ebola virus. He joined Sanofi Pasteur R&D in 2010, and has held various roles since that time, including Research Lead on the Broadly Protective Influenza Vaccine program, Head of North America B Cell Immunology/Antibody Discovery, Head of North America Biomarker Discovery and Development, Sanofi Research Representative on the Nirsevimab/Beyfortus project team, and most recently Global Project Head - mRNA Platform Development.


Day 2 - November 29 @ 10:15

Keynote Panel: SupeRNAtural: Realizing the potential of RNA therapeutics for ID & Cancer

There are a wide variety of RNA molecules used to inhibit infectious diseases and cancer, a discussion of the common challenges in:


  •   Targeting multiple antigens simultaneously
  •   Safety - More RNA = more side effects
  •   Achieving equal expression
  •   Delivering effective doses with lower amounts
  •   Combination vaccines
  •   Formulation 
  •   T-cells
last published: 02/Jan/24 12:15 GMT

back to speakers